EDIT Stock Recent News

Intellia Therapeutics and Editas Medicine are pre-revenue biotechs. Editas is a long way from commercializing its first medicine.

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle-cell disease treatment, Casgevy, utilizing gene-editing technology developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP.

Vertex Pharmaceuticals will pay Editas Medicine to license its Cas-9 gene-editing technology. Editas can still license the same technology to other companies.

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

Vertex Pharmaceuticals (NASDAQ:VRTX) shares surged more than 13% to a record higher Wednesday after the company announced an agreement to license CRISPR-Cas9 gene-editing technology from Editas Medicines,  In exchange for $100 million plus potential licensing fees, Vertex got non-exclusive licensing rights to medicines targeting the BCL11A gene in Sickle Cell Disease. That includes Casgevy, which was approved by the FDA earlier this month.

Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update December 11, 2023 1:00 PM ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmore O'Neill - CEO Baisong Mei - CMO Caren Deardorf - Chief Commercial & Strategy Officer Conference Call Participants Jack Allen - Baird Gena Wang - Barclays Joon Lee - Truist Securities Samantha Semenkow - Citigroup Yanan Zhu - Wells Fargo Luca Issi - RBC Capital Markets Phil Nadeau - TD Cowen Dae Gon Ha - Stifel Eric Schmidt - Cantor Fitzgerald Brian Cheng - J.P. Morgan Jay Olson - Oppenheimer Jingming Chen - Evercore ISI Cristi Barnett Good morning, everyone, and thank you for joining the EDIT-301 Clinical Update Webinar.

Editas Medicine is developing a promising gene-editing therapy. The biotech has several data readouts planned for the next 12 months.